Clinical Trials on High-Risk Resectable Pancreatic Cancer

Total 5537 results

Shanghai Zhongshan Hospital

Not yet recruiting

Surufatinib in Combination With Iparomlimab and Tuvonralimab Injection and AG Chemotherapy for Neoadjuvant Therapy of HRPC or BRPC (ZSPAC-22)

Borderline Resectable Pancreatic Cancer | High-Risk Resectable Pancreatic Cancer

China
Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Not yet recruiting

A Trial of SHR-8068 Combined With Adebrelimab and Apatinib in Perioperative Treatment of Resectable Hepatocellular Carcinoma

Resectable Hepatocellular Carcinoma With Intermediate or High Recurrence Risk

China
University of Arkansas

Recruiting

Intratumoral MMR Vaccine Injection in Borderline Resectable/Unresectable Pancreatic Cancer

Borderline Resectable/Unresectable Pancreatic Cancer | Non Metastatic Pancreatic Cancer

United States
Sidney Kimmel Comprehensive Cancer Center at Johns...
National Cancer Institute (NCI); Stand Up To Cancer

Active, not recruiting

Mutant KRAS -Targeted Long Peptide Vaccine for Patients at High Risk of Developing Pancreatic Cancer

Pancreatic Cancer | High Risk Cancer

United States
University of Texas Southwestern Medical Center

Completed

Adjunctive Smart Phone Based Smoking Cessation Treatment

High-Risk Cancer

This is a preview

Log in or create a free account to see all matching trials and use the full search.

Log in Register

Subscribe